Format

Send to

Choose Destination
Proteomics. 2006 Jul;6(14):4100-5.

Proteomic biomarkers for autoimmune disease.

Author information

1
Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, CA, USA. whueber@stanford.edu

Abstract

Autoimmune diseases affect 3% of the world population, yet the diagnosis and classification of autoimmune diseases remain based on clinical examination combined with traditional laboratory tests and imaging studies. The development of genomic and proteomic technologies provides an unprecedented ability to identify novel biosignatures to diagnose, classify, and guide therapeutic decision making in patients with autoimmune disease. In this article, we review recent advances in proteomics technologies and their application to autoimmune disease.

PMID:
16786488
DOI:
10.1002/pmic.200600017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center